GlassScriptPhysician profile
Chad Austin Service
NPI 1922561190
$2,497.90
in general payments reported to CMS, 2019-2025
13 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $139 · 2022: $219 · 2023: $395 · 2024: $604 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,139.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,139.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $876.40 | 2024-2025 | |
| Boston Scientific Corporation | $504.73 | 2021-2024 | Ams 700, Lithovue, Solyx Sis System |
| Medtronic, INC. | $435.67 | 2021-2025 | Interstim, Nuro |
| Endo USA, INC. | $282.45 | 2025 | Xiaflex, Aveed |
| Bayer Healthcare Pharmaceuticals INC. | $120.95 | 2025 | |
| Urogen Pharma, INC. | $69.52 | 2025 | |
| Progenics Pharmaceuticals, INC. | $64.25 | 2025 | |
| Abbvie INC. | $38.92 | 2025 | |
| Procept Biorobotics Corporation | $30.09 | 2024 | Aquabeam System |
| Merck Sharp & Dohme LLC | $21.37 | 2025 | Keytruda Qlex, Lynparza, Keytruda |
| Gilead Sciences, INC. | $19.98 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $19.54 | 2025 | Lynparza |
| Immunitybio, INC. | $14.03 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Service listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.